Detalhe da pesquisa
1.
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
PLoS Med;
17(2): e1003038, 2020 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32092060
2.
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
Lancet HIV;
11(5): e285-e299, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38692824
3.
Optimizing the Immunogenicity of HIV Vaccines by Adjuvants - NIAID Workshop Report.
Vaccine;
41(31): 4439-4446, 2023 07 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37331838
4.
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens.
Sci Rep;
10(1): 2093, 2020 02 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32034163
5.
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Lancet HIV;
5(7): e366-e378, 2018 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29898870